Occupational Exposure to Solar UVR Linked to Nonmelanoma Skin Cancer
MONDAY, Nov. 20, 2023 -- Occupational exposure to solar ultraviolet radiation (UVR) is associated with a substantial burden of nonmelanoma skin cancer (NMSC), according to a study published in the November issue of Environment International.Frank... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news

Road to RSNA 2023: Ultrasound
Ultrasound's utility will be on full display at this year's RSNA annual meeting, showing its merit in a wide variety of clinical applications. Research to be presented at the annual meeting in Chicago will explore the modality's clinical applications in musculoskeletal, pediatric, abdominal, and women's imaging among other areas. This includes advancements in ultrasound in recent years, such as the use of contrast for improved imaging, elastography and color Doppler for assessing complex pathologies, and using imaging data in AI models. Studies will also evaluate ways to further improve the modality's capabilities by rea...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 2023 Ultrasound Preview Source Type: news

High-frequency ultrasound proves efficacy of radiotherapy on skin cancer
Sunday, November 26 | 11:20 a.m.-11:30 a.m. | S2-SSRO01-6  | Room S402Here, attendees will learn about how ultrasound evaluation proves the safety and efficacy of radiotherapy for nonmelanoma skin cancer.In his presentation, Vittorio Patane, MD, from the University of Campania will present his team’s findings, which show that radiotherapy with high-frequency ultrasound imaging should be considered in treating high-risk nonmelanoma skin cancer.While surgery is the go-to method for removing these skin cancers, radiotherapy can serve as an alternative if surgery is not an option. However, there is debate on radiotherapy...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 Ultrasound Preview Source Type: news

UN Report Warns That Working in the Sun Causes Skin Cancers
THURSDAY, Nov. 9, 2023 (Healthday News) -- New data from two United Nations agencies shows that millions of workers toiling under the sun ' s glare is fueling skin cancer cases around the world.Nearly 1 in 3 deaths from non-melanoma skin cancer is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 9, 2023 Category: General Medicine Source Type: news

Melanoma now no longer the leading cause of skin cancer deaths - these are the signs you need to watch out for
Non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma, the more serious form of skin cancer, according to a team of European dermatologists. (Source: the Mail online | Health)
Source: the Mail online | Health - October 10, 2023 Category: Consumer Health News Source Type: news

Other forms of skin cancer 'killing more people than melanoma' - symptoms you need to spot
Non-melanoma skin cancer is causing a greater number of global deaths than melanoma, the more serious form of the disease, according to new findings. (Source: Daily Express - Health)
Source: Daily Express - Health - October 10, 2023 Category: Consumer Health News Source Type: news

Mum, 41, diagnosed with 'aggressive' skin cancer after noticing warning sign in selfie
A picture of Anna McCartney revealed a tell-tale sign of non-melanoma skin cancer, following years of ultraviolet light exposure. (Source: Daily Express - Health)
Source: Daily Express - Health - May 18, 2023 Category: Consumer Health News Source Type: news

Skin cancer: Health warning as non-melanoma cases rise
Public Health Wales figures show non-melanoma skin cancers increased by 7% between 2016 and 2019. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 27, 2023 Category: Consumer Health News Source Type: news

Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Dietary Antioxidants in Melanoma and Nonmelanoma Skin Cancer Dietary Antioxidants in Melanoma and Nonmelanoma Skin Cancer
Might dietary antioxidants play a role in the prevention or development of melanoma and nonmelanoma skin cancer by decreasing DNA damage caused by UV radiation?Cutis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 15, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Nicotinamide Does Not Prevent Skin Cancer After Organ Transplant Nicotinamide Does Not Prevent Skin Cancer After Organ Transplant
Although nicotinamide is often recommended, when it was put to the test, it had no efficacy in preventing nonmelanoma skin cancers among transplant recipients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 2, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Vitamin B3 Doesn't Cut Skin Cancer Risk After Organ Transplant
(MedPage Today) -- Daily treatment with nicotinamide, an active water-soluble form of vitamin B3, failed to reduce the risk of non-melanoma skin cancer in solid-organ transplant recipients with a history of skin cancer, a phase III study in Australia... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 1, 2023 Category: Cardiology Source Type: news

'Haircut could save your life': Red flag signs of cancer could appear on your scalp
There are two main types of skin cancer - non-melanoma and melanoma. (Source: Daily Express - Health)
Source: Daily Express - Health - January 26, 2023 Category: Consumer Health News Source Type: news

Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news